The antibody drug conjugates market is projected to grow at an annualized rate of over 20%, till 203

With six marketed drugs, ADCs are presently recognized as a potent class of targeted anticancer therapies, with the potential to be used to treat a variety of other disease indications. The success of such products can be attributed to their ability to effectively identify and eliminate disease associated cells / pathogens, with substantially lower risk of treatment related side effects. Over the years, various technological advancements, such as antibody engineering for site-specific conjugation and enhanced pharmacokinetic and pharmacodynamic properties, have paved the way for antibody drug conjugates (ADCs) to be recognized as potent therapies targeting a wide range of indications, including solid tumors and hematological malignancies.

To order this 600+ page report, which features 190+ figures and 280+ tables, please visit this –

The USD 15 billion (by 2030) financial opportunity within this market has been analyzed across the following segments:
 Type of Payload
 DM4
 Camptothecin
 DM1
 Others

 Type of Linker
 VC
 Sulfo-SPDB
 VA
 Hydrazone
 Others

 Target Indication
 Breast cancer
 Lymphoma
 Leukemia
 Urothelial cancer
 Lung cancer
 Ovarian cancer
 Others

 Target Antigen
 CD30
 HER2
 CD22
 CD33
 Others

 Technology Providers
 Seattle Genetics
 ImmunoGen
 StemCentRx
 Immunomedics
 Others

 Key Geographical Regions
 North America
 Europe
 Asia Pacific

The Antibody Drug Conjugates Market (5th Edition), 2019-2030.” report features the following companies, which we identified to be key players in this domain:
 Bristol Myers Squibb
 GlaxoSmithKline
 Incyte
 Novartis
 Trillium Therapeutics

Table of Contents

1. Preface

2. Executive Summary

3. Introduction

4. Market Overview

5. Company and Drug Profiles

6. Key Therapeutic Areas

7. Key Opinion Leaders